{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T19:05:32Z","timestamp":1770145532433,"version":"3.49.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To summarize the clinical characteristics of 4 male prolactinoma patients with severe obesity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical data of all the patients were retrospectively analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All the patients visited our hospital for severe obesity at the age of 16-30 years old with their body mass index (BMI) of 37.9-55.9 kg\/m<jats:sup>2<\/jats:sup>. All the patients were obese since childhood, even at birth. Hyperprolactinemia (72.3-273.0 ng\/ml) was found during the etiological\u00a0screening\u00a0of obesity and MRI revealed pituitary adenomas. Additionally, all of them had multiple obesity related complications, such as hyperinsulinemia and dyslipidemia. Treatment of dopamine agonists (DAs) effectively normalized their prolactin level and the pituitary MRI reexamination after 6 months of DAs treatment showed the shrinkage of the pituitary adenomas in 3 patients. Their weight also decreased in different degrees (2.70~19.03% lower than the baseline) with improved metabolic profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum prolactin level should be screened in obese patients, especially those with severe obesity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1285477","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:53:06Z","timestamp":1701237186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Linjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.09.001","article-title":"Association between prolactinoma and body mass index","volume":"27","author":"Al Sabie","year":"2021","journal-title":"Endocr Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11481-019-09863-0","article-title":"Dopaminergic pathways in obesity-associated inflammation","volume":"15","author":"Leite","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-007-9190-3","article-title":"Hypogonadotropic hypogonadism in a patient with morbid obesity","volume":"17","author":"Mollar Puchades","year":"2007","journal-title":"Obes Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2021.07.004","article-title":"Severe obesity caused by prolactinoma related to the abnormal insulin metabolism-A case report","volume":"15","author":"Yan","year":"2021","journal-title":"Obes Res Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2021.01.004","article-title":"Morbid obesity due to prolactinoma and significant weight loss after dopamine agonist treatment","volume":"7","author":"Ali","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.biochi.2013.09.023","article-title":"Prolactin and adipose tissue","volume":"97","author":"Carr\u00e9","year":"2014","journal-title":"Biochimie"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1060173","article-title":"Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus)","volume":"106","author":"Cincotta","year":"1985","journal-title":"J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.11.7147","article-title":"Prolactin stimulates leptin secretion by rat white adipose tissue","volume":"140","author":"Gualillo Lago","year":"1999","journal-title":"Endocrinology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902357R","article-title":"Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake","volume":"34","author":"Lopez-Vicchi","year":"2020","journal-title":"FASEB J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.883092","article-title":"Severe hyperprolactinemia promotes brown adipose tissue whitening and aggravates high fat diet induced metabolic imbalance","volume":"13","author":"Lopez-Vicchi","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-204958","article-title":"Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity","volume":"26","author":"Auffret","year":"2012","journal-title":"FASEB J"},{"key":"B13","article-title":"Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma","volume":"136","author":"Schmid","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1038\/s41598-018-22814-8","article-title":"The effect of obesity on the availabilities of dopamine and serotonin transporters","volume":"8","author":"Nam","year":"2018","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.07.018","article-title":"Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat","volume":"110","author":"Hansen","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2015.01.019","article-title":"Deep brain stimulation of the nucleus accumbens shell induces anti-obesity effects in obese rats with alteration of dopamine neurotransmission","volume":"589","author":"Zhang","year":"2015","journal-title":"Neurosci Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.06.002","article-title":"Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors","volume":"42","author":"Volkow","year":"2008","journal-title":"Neuroimage"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2191-219X-1-37","article-title":"Lower striatal dopamine D2\/3 receptor availability in obese compared with non-obese subjects","volume":"1","author":"de Weijer","year":"2011","journal-title":"EJNMMI Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00916-2","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1758-5996-6-104","article-title":"Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats","volume":"6","author":"Ezrokhi","year":"2014","journal-title":"Diabetol Metab Syndr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1285477\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:53:08Z","timestamp":1701237188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1285477\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":22,"alternative-id":["10.3389\/fendo.2023.1285477"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1285477","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"article-number":"1285477"}}